CN101939005B - 作为癌症治疗剂的驱动蛋白抑制剂 - Google Patents
作为癌症治疗剂的驱动蛋白抑制剂 Download PDFInfo
- Publication number
- CN101939005B CN101939005B CN200880120667.8A CN200880120667A CN101939005B CN 101939005 B CN101939005 B CN 101939005B CN 200880120667 A CN200880120667 A CN 200880120667A CN 101939005 B CN101939005 B CN 101939005B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- substituted
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(*=*)N(*)* Chemical compound *C(*=*)N(*)* 0.000 description 3
- WNNNWFKQCKFSDK-BYPYZUCNSA-N C=CC[C@@H](C(O)=O)N Chemical compound C=CC[C@@H](C(O)=O)N WNNNWFKQCKFSDK-BYPYZUCNSA-N 0.000 description 1
- UIHLDSYEXHQAEB-VIFPVBQESA-N C=CC[C@@H](CF)N(C(c1ccccc11)=O)C1=O Chemical compound C=CC[C@@H](CF)N(C(c1ccccc11)=O)C1=O UIHLDSYEXHQAEB-VIFPVBQESA-N 0.000 description 1
- WCZXECFPTUZDMM-YFKPBYRVSA-N C=CC[C@@H](CO)N Chemical compound C=CC[C@@H](CO)N WCZXECFPTUZDMM-YFKPBYRVSA-N 0.000 description 1
- AOIFZELMZVFVIJ-VIFPVBQESA-N C=CC[C@@H](CO)N(C(c1ccccc11)=O)C1=O Chemical compound C=CC[C@@H](CO)N(C(c1ccccc11)=O)C1=O AOIFZELMZVFVIJ-VIFPVBQESA-N 0.000 description 1
- LSUFQWSIEAGXTH-IBGZPJMESA-N CC(C)(C)[C@H](c1nc(-c(cc(cc2)F)c2F)c[n]1Cc1ccccc1)N Chemical compound CC(C)(C)[C@H](c1nc(-c(cc(cc2)F)c2F)c[n]1Cc1ccccc1)N LSUFQWSIEAGXTH-IBGZPJMESA-N 0.000 description 1
- PCUFWIFKOMVXCH-QHCPKHFHSA-N CC(C)COC(N[C@H](C(C)(C)C)c1nc(-c(cc(cc2)F)c2F)c[n]1Cc1ccccc1)=O Chemical compound CC(C)COC(N[C@H](C(C)(C)C)c1nc(-c(cc(cc2)F)c2F)c[n]1Cc1ccccc1)=O PCUFWIFKOMVXCH-QHCPKHFHSA-N 0.000 description 1
- SGFGTYXPRJBEGJ-INIZCTEOSA-N CC(C)COC(N[C@H](C(C)(C)C)c1nc(-c2cc(F)ccc2F)c[nH]1)=O Chemical compound CC(C)COC(N[C@H](C(C)(C)C)c1nc(-c2cc(F)ccc2F)c[nH]1)=O SGFGTYXPRJBEGJ-INIZCTEOSA-N 0.000 description 1
- HJWDDTDVBUFTCP-UHFFFAOYSA-N O=C(CCl)c1cc(F)ccc1F Chemical compound O=C(CCl)c1cc(F)ccc1F HJWDDTDVBUFTCP-UHFFFAOYSA-N 0.000 description 1
- XNUXSAGMXTXYOS-QMMMGPOBSA-N O=CC[C@@H](CF)N(C(c1c2cccc1)=O)C2=O Chemical compound O=CC[C@@H](CF)N(C(c1c2cccc1)=O)C2=O XNUXSAGMXTXYOS-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1396607P | 2007-12-14 | 2007-12-14 | |
| US61/013,966 | 2007-12-14 | ||
| PCT/EP2008/067412 WO2009077448A1 (en) | 2007-12-14 | 2008-12-12 | Kinesin inhibitors as cancer therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101939005A CN101939005A (zh) | 2011-01-05 |
| CN101939005B true CN101939005B (zh) | 2015-12-16 |
Family
ID=40328566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880120667.8A Expired - Fee Related CN101939005B (zh) | 2007-12-14 | 2008-12-12 | 作为癌症治疗剂的驱动蛋白抑制剂 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8252832B2 (enExample) |
| EP (1) | EP2229170B1 (enExample) |
| JP (1) | JP5501976B2 (enExample) |
| KR (1) | KR20100098394A (enExample) |
| CN (1) | CN101939005B (enExample) |
| AR (1) | AR069676A1 (enExample) |
| AU (1) | AU2008337570B2 (enExample) |
| BR (1) | BRPI0821248A2 (enExample) |
| CA (1) | CA2708822A1 (enExample) |
| CL (1) | CL2008003707A1 (enExample) |
| CO (1) | CO6290651A2 (enExample) |
| CR (1) | CR11412A (enExample) |
| DO (1) | DOP2010000175A (enExample) |
| EA (1) | EA018014B1 (enExample) |
| EC (1) | ECSP10010248A (enExample) |
| ES (1) | ES2459442T3 (enExample) |
| GE (1) | GEP20125647B (enExample) |
| GT (1) | GT201000172A (enExample) |
| IL (1) | IL205831A0 (enExample) |
| MA (1) | MA31872B1 (enExample) |
| MY (1) | MY150214A (enExample) |
| NI (1) | NI201000091A (enExample) |
| NZ (1) | NZ585142A (enExample) |
| PA (1) | PA8807801A1 (enExample) |
| PE (1) | PE20091451A1 (enExample) |
| SM (1) | SMP201000095B (enExample) |
| TN (1) | TN2010000204A1 (enExample) |
| TW (1) | TW200930704A (enExample) |
| UY (1) | UY31532A1 (enExample) |
| WO (1) | WO2009077448A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765817B1 (en) | 2008-12-03 | 2014-07-01 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| US8349899B1 (en) | 2008-12-03 | 2013-01-08 | Arrowhead Center, Inc. | Selective inhibitors of EG5 motors and methods of use |
| JP2013525290A (ja) * | 2010-04-15 | 2013-06-20 | ノバルティス アーゲー | Ｋｓｐ阻害剤としてのオキサゾールおよびチアゾール化合物 |
| CN105451773A (zh) * | 2013-03-15 | 2016-03-30 | 诺华股份有限公司 | 细胞增殖抑制剂及其缀合物 |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| PE20180610A1 (es) * | 2015-06-22 | 2018-04-09 | Bayer Pharma AG | CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES |
| CN105418527A (zh) * | 2015-12-28 | 2016-03-23 | 青岛友诚高新技术有限公司 | 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途 |
| CN105646361B (zh) * | 2016-02-17 | 2017-12-01 | 吉首大学 | 一种2,4,5‑三芳基咪唑型化合物及其制法和用途 |
| IL310558B1 (en) | 2016-12-21 | 2025-10-01 | Bayer Pharma AG | Antibody-drug conjugates with enzymatically cleavable groups |
| CN106668863B (zh) * | 2017-02-21 | 2019-04-23 | 南方医科大学 | 靶向ktn1治疗皮肤鳞状细胞癌的药物 |
| GB201706162D0 (en) * | 2017-04-19 | 2017-05-31 | Nat Univ Singapore | Compounds |
| WO2019196111A1 (zh) * | 2018-04-13 | 2019-10-17 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物 |
| CN109646679A (zh) * | 2019-01-28 | 2019-04-19 | 中国科学院长春应用化学研究所 | 铁离子螯合剂及其可药用盐的用途 |
| CN111529526B (zh) * | 2020-04-14 | 2021-04-23 | 广州领晟医疗科技有限公司 | 一种化合物在制备治疗急性胰腺炎的药物中的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021794A1 (en) * | 2005-08-09 | 2007-02-22 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
| CN1993331A (zh) * | 2004-06-18 | 2007-07-04 | 希龙公司 | N－(1－(1－苄基－4－苯基－1h－咪唑－2－基 )－2 , 2－二甲基丙基)苯甲酰胺衍生物和相关化合物作为用于治疗癌症的驱动蛋白纺锤蛋白(ksp)抑制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7271271B2 (en) | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| KR20090097210A (ko) | 2007-01-05 | 2009-09-15 | 노파르티스 아게 | 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체 |
-
2008
- 2008-11-25 US US12/313,923 patent/US8252832B2/en not_active Expired - Fee Related
- 2008-12-12 WO PCT/EP2008/067412 patent/WO2009077448A1/en not_active Ceased
- 2008-12-12 AR ARP080105410A patent/AR069676A1/es not_active Application Discontinuation
- 2008-12-12 KR KR1020107012912A patent/KR20100098394A/ko not_active Withdrawn
- 2008-12-12 PE PE2008002064A patent/PE20091451A1/es not_active Application Discontinuation
- 2008-12-12 CN CN200880120667.8A patent/CN101939005B/zh not_active Expired - Fee Related
- 2008-12-12 TW TW097148535A patent/TW200930704A/zh unknown
- 2008-12-12 GE GEAP200811846A patent/GEP20125647B/en unknown
- 2008-12-12 NZ NZ585142A patent/NZ585142A/en not_active IP Right Cessation
- 2008-12-12 CA CA2708822A patent/CA2708822A1/en not_active Abandoned
- 2008-12-12 EP EP08863009.0A patent/EP2229170B1/en active Active
- 2008-12-12 AU AU2008337570A patent/AU2008337570B2/en not_active Ceased
- 2008-12-12 EA EA201000900A patent/EA018014B1/ru not_active IP Right Cessation
- 2008-12-12 MY MYPI2010002030A patent/MY150214A/en unknown
- 2008-12-12 JP JP2010537460A patent/JP5501976B2/ja not_active Expired - Fee Related
- 2008-12-12 PA PA20088807801A patent/PA8807801A1/es unknown
- 2008-12-12 CL CL2008003707A patent/CL2008003707A1/es unknown
- 2008-12-12 BR BRPI0821248-1A patent/BRPI0821248A2/pt not_active IP Right Cessation
- 2008-12-12 ES ES08863009.0T patent/ES2459442T3/es active Active
- 2008-12-15 UY UY31532A patent/UY31532A1/es not_active Application Discontinuation
-
2010
- 2010-05-05 CR CR11412A patent/CR11412A/es not_active Application Discontinuation
- 2010-05-07 TN TN2010000204A patent/TN2010000204A1/fr unknown
- 2010-05-17 IL IL205831A patent/IL205831A0/en unknown
- 2010-05-31 MA MA32879A patent/MA31872B1/fr unknown
- 2010-06-02 NI NI201000091A patent/NI201000091A/es unknown
- 2010-06-10 CO CO10070369A patent/CO6290651A2/es not_active Application Discontinuation
- 2010-06-11 DO DO2010000175A patent/DOP2010000175A/es unknown
- 2010-06-14 GT GT201000172A patent/GT201000172A/es unknown
- 2010-06-14 EC EC2010010248A patent/ECSP10010248A/es unknown
- 2010-07-13 SM SM201000095T patent/SMP201000095B/it unknown
-
2012
- 2012-07-11 US US13/546,713 patent/US8664256B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1993331A (zh) * | 2004-06-18 | 2007-07-04 | 希龙公司 | N－(1－(1－苄基－4－苯基－1h－咪唑－2－基 )－2 , 2－二甲基丙基)苯甲酰胺衍生物和相关化合物作为用于治疗癌症的驱动蛋白纺锤蛋白(ksp)抑制剂 |
| WO2007021794A1 (en) * | 2005-08-09 | 2007-02-22 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Anthony B Pinkerton.Imidazole based kinesin spindle protein inhibitors.《Expert Opin. Ther. Patents》.2007,第17卷(第7期),875-878. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101939005B (zh) | 作为癌症治疗剂的驱动蛋白抑制剂 | |
| US5645988A (en) | Methods of identifying drugs with selective effects against cancer cells | |
| US20240343682A1 (en) | Pcna inhibitors | |
| US11267809B2 (en) | BAF complex modulating compounds and methods of using the same | |
| US12258360B2 (en) | Compositions and methods for treatment of anticancer-drug resistant cancers | |
| WO2010077310A2 (en) | Amide derivatives of ethacrynic acid | |
| US20140056880A1 (en) | Triazole compounds as ksp inhibitors | |
| US20150374646A1 (en) | Treatment of cancer and other conditions using a transcription factor modulator | |
| US20080318938A1 (en) | Methods for treating aberrant cell proliferation disorders | |
| US8772321B2 (en) | Heteroannelated anthraquinone derivatives for inhibiting cancers | |
| US20210379047A1 (en) | Combination Therapies For Treating Cancer | |
| US20230227418A1 (en) | Usp9x inhibitors | |
| US11691945B2 (en) | USP9X inhibitors | |
| US20240374574A1 (en) | Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy | |
| US20240294467A1 (en) | USP9X Inhibitors | |
| US9309247B2 (en) | 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer | |
| WO2025132831A1 (en) | N-heteroaryl derivatives and uses thereof for treating cancer | |
| HK1258659B (en) | Pcna inhibitors | |
| HK1258659A1 (en) | Pcna inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151216 Termination date: 20181212 |